Clinical Trial: Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07907211) titled 'Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma' on Oct. 08.

Brief Summary: The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.

The main questions it aims to answer are:

Does rivaroxaban reduce the incidence of venous thromboembolism (VTE) compared with aspirin in this patient population?

What are the comparative safety profiles (particularly regarding bleeding events) of aspirin and rivaroxaban in this setting?

Study Start Date: Feb. 01, 2024...